NCT00832390View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 14, 2007

Primary Completion Date

July 11, 2008

Study Completion Date

July 11, 2008

Conditions

Diabetes Mellitus

Interventions

DRUG

sitagliptin phosphate

Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00832390 - Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158) | Biotech Hunter | Biotech Hunter